Abstract Number: PB0367
Meeting: ISTH 2020 Congress
Background: Primary Myelofibrosis (PMF) is philadelphia-negative myeloproliferative neoplasm with unique symptoms caused by bone marrow fibrosis. Thrombocytosis and leukocytosis are specific symptoms for PMF and appointment of specific therapy to PMF patients leads to reduce number of cells. Activation and damage of blood cells associate with microparticles (MP) release. Tissue factor (TF) and procoagulant phospholipids (PL) on MP surface can increase prothrombogenic potential of blood plasma.
Aims: To value influence of specific therapy on microparticle-associated thrombin generation in PMF patients.
Methods: The study included 46 PMF patients (38 – 78 years, median of age = 57,8). 24 patients (group 1) were given specific therapy (ruxolitinib and hydroxycarbamide) and 22 patients (group 2) were not. Thrombin generation was measured in platelet-free plasma with Calibrated Automated Thrombinography (CAT) according to Hemker et al. We used following reagents: «FluCa‑kit», «PRP-reagent», containing rTF (1pM), «MP-reagent», containing negatively charged phospholipids (4µM) with CTI (40 µ/ml). Endogenous thrombin potential (ETP, nM*min) and peak thrombin (Peak, nM) were evaluated.
STATISTICA 12.0 package was used in data analysis. The results are presented in the table as median with 95% confidence intervals, p< 0.05 was considered statistically significant (*).
Results: Significant differences were found when were used «PRP-reagent» allowing to estimate thrombin generation which depends on PL. ETP and Peak thrombin were lower in the group of patients on specific therapy. «MP-Reagent» allows to evaluate thrombin generation caused by TF. ETP and Peak had tendency to decrease in the group 1 compared the group 2 when «MP-Reagent» was used (p=0,26 and p=0,36, respectively).
Conclusions: Specific therapy in patients with PMF leads to reduce of microparticle-associated thrombin generation. It can be associated with decline prothrombogenic potential of blood plasma and make significance for less development of thrombotic complications under specific therapy in patients with PMF.
|Parameters||«PRP-Reagent» Group1||«PRP-Reagent» Group2||«MP-Reagent» Group1||«MP-Reagent» Group2|
|ETP (nM·min)||304,9* (102,7-1176,1)||557,0 (200,9-1306,9)||631,0 (305,0-1694,5)||968,2 (230,8-1881,5)|
|Peak(nМ)||12,1* (2,9-66,92)||25,75 (8,1-59,54)||62,3 (19,0-300,2)||104,67 (17,6-336,39)|
[Thrombogram parameters in the groups of patients (Me, 95% CI)]
To cite this abstract in AMA style:Matvienko O, Silina N, Korsakova N, Golovina O, Papayan L, Efremova E, Fominyh M, Shuvaev V, Voloshin S. Influence of Specific Therapy on Microparticle-Associated Thrombin Generation in Patients with Primary Myelofibrosis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/influence-of-specific-therapy-on-microparticle-associated-thrombin-generation-in-patients-with-primary-myelofibrosis/. Accessed August 15, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/influence-of-specific-therapy-on-microparticle-associated-thrombin-generation-in-patients-with-primary-myelofibrosis/